Search clinical trials for: BMS-986165 Tablet

Total 10433 results

Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Psoriasis

Japan
Bristol-Myers Squibb

Completed

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

Renal Impairment | Healthy Volunteer

United States, Czechia, Hungary, Poland
Bristol-Myers Squibb

Completed

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

Psoriasis

United States
Bristol-Myers Squibb

Recruiting

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF)

Heart Failure

United States, Spain, Canada, Italy, Poland
Bristol-Myers Squibb

Terminated

Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Healthy Volunteers | Ulcerative Colitis

Australia, Georgia, Moldova, Republic of
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Russian Federation, United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Finland, France, Hungary, Ireland, Italy, Mexico, Poland, Romania, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE)

Psoriasis

China, Taiwan, Spain, United States, Hungary, Canada, Germany, Japan, Australia, Poland, Czechia, United Kingdom, Korea, Republic of, Israel, New Zealand, Sweden, France, Finland, Russian Federation, Puerto Rico
Bristol-Myers Squibb

Completed

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

Autoimmune Diseases

China
Yiling Pharmaceutical Inc.

Completed

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Parkinson Disease

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Ronald Levy
National Cancer Institute (NCI)

Active, not recruiting

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | B-Cell Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma

United States
University Medical Center Groningen

Completed

PD-L1 PET Imaging in Melanoma Patients

Melanoma

Netherlands
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)

Bulgaria, United States
Bristol-Myers Squibb

Completed

A Taste Assessment of BMS-986165 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting (ARTISTYK)

Psoriasis

United States, Puerto Rico
Bristol-Myers Squibb

Terminated

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, Canada, Germany, Poland, Puerto Rico, United Kingdom, Netherlands
ViiV Healthcare

Completed

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Bristol-Myers Squibb

Completed

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage

Healthy Volunteers | Liver Dysfunction

Czechia, Hungary, Slovakia
The National Institutes of Pharmaceutical R&D Co...

Completed

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Idiopathic Pulmonary Fibrosis

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants

Healthy Volunteers

United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Bristol-Myers Squibb

Completed

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Arthritis

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Terminated

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Crohn's Disease | Granulomatous Colitis | Crohn's Enteritis | Granulomatous Enteritis

Canada, Germany, Taiwan, United States, Spain, Australia, Poland, Russian Federation, Japan, Korea, Republic of, Romania, Italy, United Kingdom, Belgium, Brazil, China, Czechia, France, Hungary, Ireland, Israel, Mexico, Netherlands, P... and more
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

Advanced Solid Tumors

United States, Chile, Argentina, Belgium, Canada, Japan, Netherlands
Biogen

Terminated

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)

Alzheimer's Disease

United States, Spain, Italy, Australia, France, Poland, Germany, Japan, Sweden
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Ischemic Stroke

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Advanced Cancer

Japan
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb

Recruiting

Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

Hidradenitis Suppurativa

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet

Healthy Volunteers

United States
Atridia Pty Ltd.

Completed

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Inflammatory Bowel Disease

Australia
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

Solid Tumors

United States, Australia, Spain, Germany, France, Switzerland, Netherlands, Canada, Belgium, Italy
Bristol-Myers Squibb

Completed

Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects

Rheumatoid Arthritis

Australia
Bristol-Myers Squibb

Completed

Study of Relatlimab in Combination With Nivolumab in Chinese Participants (RELATIVITY-111)

Advanced Solid Tumors

China
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Cancer

Japan
Harmony Biosciences, LLC

Active, not recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Prader-Willi Syndrome

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Malignant Solid Tumor

United States, France, Italy, Australia, Canada, Germany, Netherlands
Bristol-Myers Squibb

Terminated

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Hepatocellular Carcinoma

Canada, Singapore, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Cancer

United States
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Bristol-Myers Squibb

Completed

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986195 in Healthy Male Subjects

Rheumatoid Arthritis

Netherlands
Bristol-Myers Squibb

Completed

Effect of BMS-986165 on the Blood Levels of Metformin

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Study of BMS-986158 in Subjects With Select Advanced Cancers (BET)

Advanced Tumors

United States, France, Australia, Spain, Canada
Bristol-Myers Squibb

Completed

A Study to Evaluate the Bioavailability of BMS-986205

Healthy Participants

United Kingdom
Rigshospitalet, Denmark

Completed

The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.

Hyponatremia | Metabolic Bone Disease

Denmark
M.D. Anderson Cancer Center

Recruiting

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Renal Medullary Carcinoma | Carcinomas

United States
Paratek Pharmaceuticals Inc

Active, not recruiting

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Mycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary Infection

United States

3

Subscribe